| Malignant neoplasm of prostate
Eligard vs Posluma
Side-by-side clinical, coverage, and cost comparison for malignant neoplasm of prostate.Deep comparison between: Eligard vs Posluma with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsPosluma has a higher rate of injection site reactions vs Eligard based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Posluma but not Eligard, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Eligard
Posluma
At A Glance
SC injection
Every 1-6 months
GnRH agonist
IV injection
PSMA-targeted radiodiagnostic
Indications
- Malignant neoplasm of prostate
- Malignant neoplasm of prostate
Dosing
Malignant neoplasm of prostate 7.5 mg SC once every month; 22.5 mg SC once every 3 months; 30 mg SC once every 4 months; 45 mg SC once every 6 months. Injection site should vary periodically in the upper- or mid-abdominal area, upper buttocks, or another location with adequate subcutaneous tissue.
Malignant neoplasm of prostate 296 MBq (8 mCi) as a single intravenous bolus injection; begin imaging approximately 60 minutes after administration from mid-thigh to base of skull.
Contraindications
- Hypersensitivity to GnRH, GnRH agonist analogs, or any component of ELIGARD
—
Adverse Reactions
Most common (>2%) Hot flashes/sweats, malaise and fatigue, testicular atrophy, weakness, dizziness, nausea, urinary frequency, nocturia, pruritus, myalgia, gynecomastia, decreased libido
Injection site Transient burning/stinging, pain, erythema, bruising, pruritus, induration, ulceration
Postmarketing Pituitary apoplexy, convulsions, interstitial lung disease
Most common (>=0.4%) Diarrhea, blood pressure increase, injection site pain
Pharmacology
Leuprolide acetate is a GnRH agonist that potently inhibits gonadotropin secretion with continuous dosing; chronic administration suppresses LH and FSH, reducing testosterone to below castrate threshold (<=50 ng/dL) in males within two to four weeks of treatment initiation.
PSMA-targeted radiodiagnostic agent; flotufolastat F 18 binds to PSMA (IC50 = 4.4 nM) on prostate cancer cells, which overexpress PSMA, and is internalized; fluorine-18 emits positrons detectable by PET.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Eligard
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (9/12)
No coverage data available for Posluma.
UnitedHealthcare
Eligard
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (2/8)
No coverage data available for Posluma.
Humana
Eligard
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
No coverage data available for Posluma.
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Prostate Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Posluma.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EligardView full Eligard profile
PoslumaView full Posluma profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.